Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4139 Biotechnology

Trading 06-02 09:36:02 EDT

69.82

-0.86

-1.22%

High70.68	Low69.67	Vol117.88M
Open70.68	D1 Closing70.68	Amplitude1.43%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O1.13B	T/O Rate--	Tradable Shares0.00
P/B6.880241	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"Biotechnology","latestPrice":69.81837,"timestamp":1780407362217,"preClose":70.682236,"halted":0,"volume":117878647,"delay":0,"changeRate":-0.012222,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-0.863869,"latestTime":"06-02 09:36:02 EDT","open":70.68235,"high":70.68235,"low":69.673164,"amount":1128321586.412472,"amplitude":0.014278,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1780430400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.880241,"peRate":-149.275441,"turnoverRate":0.00356,"increases":103,"decrements":387,"flats":23,"marketCap":1788932609059.6562,"floatMarketCap":1605555713969.586},"requestUrl":"/m/hq/s/BK4139","defaultTab":"news","newsList":[{"id":"2640916621","title":"Crinetics to present up to 2-year PATHFNDR open-label extension data on oral acromegaly drug Palsonify at ENDO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640916621","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640916621?lang=en_us&edition=fundamental","pubTime":"2026-06-02 16:55","pubTimestamp":1780390524,"startTime":"0","endTime":"0","summary":"Crinetics outlined six ENDO 2026 presentations, led by longer-term open-label extension results for PALSONIFY  in acromegaly.Results will be presented June 13-16, 2026 in Chicago, including data extending to two years from PATHFNDR-1 and PATHFNDR-2.The PALSONIFY readout is positioned to reinforce durable disease control with a safety profile consistent with longer-term use, supporting commercial uptake post U.S. and E.U. launches.Atumelnant oral presentations will disclose full Phase 2 congenital adrenal hyperplasia results, highlighting potential to reduce steroid burden while maintaining hormonal control.Additional atumelnant updates in ACTH-dependent Cushing’s syndrome will present interim findings supporting a block-and-replace strategy, informing late-stage development decisions.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL87Zr1P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","SG9999014039.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014021.USD","LU2095319765.USD","BK4588","SG9999014013.SGD","BK4112","NDAQ","SG9999014005.SGD","LU0314104364.USD","BK4007","IE00BN0W2V16.EUR","LU2210149790.SGD","BK4585","IE00B64PRP62.GBP","CRNX","BK4139","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640915131","title":"Sino Biopharmaceutical Stock Slides 1.4% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2640915131","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640915131?lang=en_us&edition=fundamental","pubTime":"2026-06-02 16:33","pubTimestamp":1780389180,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. slipped 1.4% to 4.88 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 2.5% to 26038.32.This was the stock's second consecutive day of losses.Sino Biopharmaceutical Ltd. closed 46% short of its 52-week high of HK$9.12, which the company achieved Sept. 10.The stock underperformed when compared to some of its competitors, as CSPC Pharmaceutical Group Ltd. fell 0.1% and Amgen Inc. remained unchanged.Trading volume totaled 70.0 million shares, compared to the 50-day average of 78.9 million shares.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU0320765992.SGD","LU1023059063.AUD","LU1571399168.USD","BK1589","LU2112291526.USD","LU0058720904.USD","BK4588","LU2089984988.USD","LU2242646821.SGD","IE00B4R5TH58.HKD","BK1521","LU0889565916.HKD","BK1515","BK4139","BK4599","LU0868494617.USD","LU0289739699.SGD","IE00BJJMRZ35.SGD","BK4566","HK0000165453.HKD","LU1061106388.HKD","LU0122379950.USD","LU2468319806.SGD","01177","AMGN","BK4533","BK4585","IE00BZ08YS42.EUR","LU2242652126.USD","IE00BFTCPJ56.SGD","SG9999001440.SGD","BK4534","LU1057294990.SGD","IE0002141913.USD","IE0009355771.USD","BK1191","IE00BZ08YT58.USD","IE00BJT1NW94.SGD","BK4581","LU1983299246.USD","LU0109394709.USD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640791310","title":"AbbVie says EU Commission approves Aquipta for acute migraine treatment in adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2640791310","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640791310?lang=en_us&edition=fundamental","pubTime":"2026-06-02 16:02","pubTimestamp":1780387349,"startTime":"0","endTime":"0","summary":"AbbVie won European Commission clearance for AQUIPTA  for acute migraine treatment in adults, taken as needed.The EU label now covers both acute use and once-daily prevention for adults with at least four migraine days per month.Approval was supported by Phase 3 ECLIPSE data showing superior two-hour pain freedom versus placebo, with sustained relief through 48 hours.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL136T1F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","LU1057294990.SGD","LU1585245621.USD","LU1839511570.USD","IE00B19Z3581.USD","IE00B4R5TH58.HKD","BK4550","IE00BN8TJ469.HKD","BK4559","LU1037948897.HKD","LU1929549753.HKD","LU2023251221.USD","SG9999001440.SGD","LU0456855351.SGD","LU0868494708.USD","LU0912757837.SGD","LU0310800379.SGD","IE00BLSP4452.SGD","LU1244550221.USD","LU0820561909.HKD","LU1934455863.HKD","LU0029864427.USD","LU0965509283.SGD","LU1732799900.SGD","LU0198837287.USD","LU0965509101.SGD","LU1496350171.SGD","LU1718418525.SGD","LU0820561818.USD","LU0689472784.USD","SG9999011175.SGD","ABBV","IE000SO60NU8.SGD","LU0943347566.SGD","LU2347655156.SGD","BK4139","IE000F7OJYX1.SGD","IE00BLSP4239.USD","LU0859254822.USD","LU2468319806.SGD","IE00BFTCPJ56.SGD","LU0124676726.USD","LU1934455277.USD","LU0795875169.SGD","LU0057025933.USD","LU2129689431.USD","LU0114720955.EUR","LU0058720904.USD","IE0002270589.USD","LU0158827948.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640751913","title":"Colliers releases 2025 Global Sustainability Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2640751913","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640751913?lang=en_us&edition=fundamental","pubTime":"2026-06-02 16:00","pubTimestamp":1780387200,"startTime":"0","endTime":"0","summary":"Highlights emissions reductions and progress in delivering long-term valueTORONTO, June  02, 2026  (GLOBE NEWSWIRE) -- Colliers (NASDAQ, TSX: CIGI) released its 2025 Global Sustainability Report, demo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3304880/0/en/Colliers-releases-2025-Global-Sustainability-Report.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CIGI","BK4079","GRI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640913560","title":"U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik","url":"https://stock-news.laohu8.com/highlight/detail?id=2640913560","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640913560?lang=en_us&edition=fundamental","pubTime":"2026-06-02 15:49","pubTimestamp":1780386551,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik June 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Edgewise","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nL4N42A0K5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1035773651.USD","HPE","FULC","BK4524","LU0198837287.USD","BK4023","RVMD","ORCU","U","LU0109394709.USD","BK4088","RBRK","ODTX","OCTV","LU0353189680.USD","XFOR","EWTX","EVR","IE0002270589.USD","LU1894683348.USD","CZR","BK4602","MOBI","TMHC","MLM","SAIL","ORCX","SOC","LU0738911758.USD","IBM","VMC","MAC","IE00B775SV38.USD","PRAX","ORCS","LU0234570918.USD","ORCL","BK4566","TTWO","LU2506951875.HKD","CHWY","MANE","UNX","LU1883839398.USD","NAVN","LU0061475181.USD","SAIC","LTH","BK4561","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640435913","title":"Neurizon Therapeutics Seeks ASX Quotation for 7.7 Million New Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2640435913","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640435913?lang=en_us&edition=fundamental","pubTime":"2026-06-02 15:48","pubTimestamp":1780386485,"startTime":"0","endTime":"0","summary":"The latest update is out from Pharmaust Limited ( ($AU:NUZ) ). Neurizon Therapeutics Limited has applied to the ASX for quotation of 7,708,526 new ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurizon-therapeutics-seeks-asx-quotation-for-7-7-million-new-shares?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurizon-therapeutics-seeks-asx-quotation-for-7-7-million-new-shares?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640791835","title":"UBS Group Exits Substantial Holder Position in EQ Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2640791835","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640791835?lang=en_us&edition=fundamental","pubTime":"2026-06-02 15:18","pubTimestamp":1780384723,"startTime":"0","endTime":"0","summary":"EQ Resources Limited ( ($AU:EQR) ) has provided an announcement. UBS Group AG and its related bodies corporate have lodged a notice stating they ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ubs-group-exits-substantial-holder-position-in-eq-resources?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ubs-group-exits-substantial-holder-position-in-eq-resources?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","LU1863844749.USD","BK4568","BK4585","UBS","BK4118","LU1829250122.USD","EQ","IE0034235071.USD","BK4588","LU3187612489.SGD","LU1863844665.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640997218","title":"Beone Medicines : RBC Raises Target Price to $436 From $425","url":"https://stock-news.laohu8.com/highlight/detail?id=2640997218","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640997218?lang=en_us&edition=fundamental","pubTime":"2026-06-02 14:32","pubTimestamp":1780381950,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nFWN42A03G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONC","BK0239","688235","BK4588","BK4526","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640088997","title":"Nanobiotix Joins the Euronext Tech Leaders Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2640088997","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640088997?lang=en_us&edition=fundamental","pubTime":"2026-06-02 14:30","pubTimestamp":1780381800,"startTime":"0","endTime":"0","summary":"PARIS and CAMBRIDGE, Mass., June  02, 2026  (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic appro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3304858/0/en/Nanobiotix-Joins-the-Euronext-Tech-Leaders-Index.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4156","BK4139","NBTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640569997","title":"OXB Capital Markets Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2640569997","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640569997?lang=en_us&edition=fundamental","pubTime":"2026-06-02 14:00","pubTimestamp":1780380000,"startTime":"0","endTime":"0","summary":"OXB to demonstrate how its global, multi-vector CDMO platform is positioned to capture growth in the cell and gene therapy marketEvent to highlight OXB’s proven track record, leading technical capabil","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3304849/0/en/OXB-Capital-Markets-Event.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640999299","title":"Praxis Precision Medicines Inc : Baird Cuts Target Price to $400 From $433","url":"https://stock-news.laohu8.com/highlight/detail?id=2640999299","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640999299?lang=en_us&edition=fundamental","pubTime":"2026-06-02 11:04","pubTimestamp":1780369499,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nFWN42912Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","LU0320765992.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU0109394709.USD","IE0002141913.USD","PRAX","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640996010","title":"Dual Insider Moves Shake Up Sensei Biotherapeutics Investor Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2640996010","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640996010?lang=en_us&edition=fundamental","pubTime":"2026-06-02 10:12","pubTimestamp":1780366342,"startTime":"0","endTime":"0","summary":"New insider activity at Sensei Biotherapeutics ( ($SNSE) ) has taken place on June 1, 2026. Sensei Biotherapeutics has seen notable insider activit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/dual-insider-moves-shake-up-sensei-biotherapeutics-investor-watch-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/dual-insider-moves-shake-up-sensei-biotherapeutics-investor-watch-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNSE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640957679","title":"Outlook Therapeutics beneficial owner Ghiath M. Sukhtian reports $5 million common share purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2640957679","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640957679?lang=en_us&edition=fundamental","pubTime":"2026-06-02 09:30","pubTimestamp":1780363847,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics director and 10% owner Ghiath M. Sukhtian reported an indirect purchase of 8,539,709 common shares at USD 0.59.Indirect beneficial ownership rose to 22,092,068 common shares.Warrants held indirectly were reset to a USD 0.59 exercise price, covering 15,488,570 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDLb19B5v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Outlook Therapeutics beneficial owner Ghiath M. Sukhtian reports $5 million common share purchase","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640309996","title":"Notification of cessation of securities - AVH-RCEL.O","url":"https://stock-news.laohu8.com/highlight/detail?id=2640309996","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640309996?lang=en_us&edition=fundamental","pubTime":"2026-06-02 09:25","pubTimestamp":1780363509,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260602:nASX7hTfsM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nASX5GjYmg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640995610","title":"Q32 Bio director and 10% owner Diyong Xu acquires $15 million in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2640995610","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640995610?lang=en_us&edition=fundamental","pubTime":"2026-06-02 09:16","pubTimestamp":1780362991,"startTime":"0","endTime":"0","summary":"Q32 Bio director Xu Diyong reported purchases of 1.88 million common shares at $8 per share in a private placement.Indirect holdings rose to 3,502,987 shares in one account, with a separate indirect position of 625,000 shares reported.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL3Z0f5l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QTTB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640499555","title":"OrbiMed Advisors acquires Q32 Bio common shares worth $15 million in private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2640499555","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640499555?lang=en_us&edition=fundamental","pubTime":"2026-06-02 09:13","pubTimestamp":1780362813,"startTime":"0","endTime":"0","summary":"OrbiMed Advisors, a director and 10% owner, bought 1.88 million Q32 Bio common shares in a private placement at USD 8 each.Indirect beneficial ownership rose to 3.5 million shares held via OrbiMed Private Investments VII.A separate OrbiMed Genesis position totaled 625,000 shares following the purchase.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDLGmG10:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"OrbiMed Advisors acquires Q32 Bio common shares worth $15 million in private placement","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640906993","title":"Telix Pharmaceuticals Says Prostate Cancer Treatement Candidate Shows Acceptable Tolerability in Phase Three Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640906993","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640906993?lang=en_us&edition=fundamental","pubTime":"2026-06-02 08:38","pubTimestamp":1780360721,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) said its lutetium radio antibody-drug conjugate candidate, TLX591-Tx, demonstrated acceptable tolerability across all standard-of-care combination groups in the ProstAC","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX","IND.AU","BK4139","BK7095","TLX.AU","BK7067","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640993128","title":"Ironwood Pharmaceuticals Signals Blockbuster Momentum in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640993128","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640993128?lang=en_us&edition=fundamental","pubTime":"2026-06-02 08:30","pubTimestamp":1780360215,"startTime":"0","endTime":"0","summary":"Ironwood Pharmaceuticals (($IRWD)) has held its Q1 earnings call. Read on for the main highlights of the call. Ironwood Pharmaceuticals’ latest ear...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ironwood-pharmaceuticals-signals-blockbuster-momentum-in-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ironwood-pharmaceuticals-signals-blockbuster-momentum-in-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRWD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640995058","title":"Assessing Conexeu Sciences (CNXU) Valuation After Launch Of Preclinical B.R.E.A.S.T. Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2640995058","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640995058?lang=en_us&edition=fundamental","pubTime":"2026-06-02 08:29","pubTimestamp":1780360190,"startTime":"0","endTime":"0","summary":"Conexeu Sciences (CNXU) has drawn fresh attention after launching a preclinical development program for its 3D printed B.R.E.A.S.T. bioregenerative breast matrix at the Wake Forest Institute for Regenerative Medicine.\nSee our latest analysis for Conexeu Sciences.\nThe recent preclinical program launch and the stock’s addition to the Nasdaq Composite Index have coincided with a 1 day share price return of 20.43% to US$14.12. However, the year to date share price return of 8.03% and a 7 day...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cnxu/conexeu-sciences/news/assessing-conexeu-sciences-cnxu-valuation-after-launch-of-pr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cnxu/conexeu-sciences/news/assessing-conexeu-sciences-cnxu-valuation-after-launch-of-pr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640995215","title":"A Look At ACI Worldwide (ACIW) Valuation After UBX Tanzania Partnership Extension","url":"https://stock-news.laohu8.com/highlight/detail?id=2640995215","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640995215?lang=en_us&edition=fundamental","pubTime":"2026-06-02 08:29","pubTimestamp":1780360184,"startTime":"0","endTime":"0","summary":"ACI Worldwide (ACIW) is back in focus after extending its nearly 20 year partnership with UBX Tanzania. The deal is centered on payments infrastructure resilience, scalability, and new digital services in a growing African market.\nSee our latest analysis for ACI Worldwide.\nThe recent 1 day share price return of 3.11% and 7 day share price return of 5.41% put ACI Worldwide at US$45.03. A 3 year total shareholder return of 96.29% contrasts with a modest decline in year to date share price...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nasdaq-aciw/aci-worldwide/news/a-look-at-aci-worldwide-aciw-valuation-after-ubx-tanzania-pa","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nasdaq-aciw/aci-worldwide/news/a-look-at-aci-worldwide-aciw-valuation-after-ubx-tanzania-pa","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1815336091.USD","BK4023","ACIW","UBX","LU0963586101.USD","BK4113","BK4139","LU0757428866.USD","ACI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0173},{"period":"1month","weight":0.0526},{"period":"3month","weight":0.115},{"period":"6month","weight":0.1092},{"period":"1year","weight":0.287},{"period":"ytd","weight":0.1124}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4139","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biotechnology,BK4139,Biotechnology股票,Biotechnology股票老虎,Biotechnology股票老虎国际,Biotechnology行情,Biotechnology股票行情,Biotechnology股价,Biotechnology股市,Biotechnology股票价格,Biotechnology股票交易,Biotechnology股票购买,Biotechnology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}